Enterprise Ireland Innovative HPSU Fund

The Innovative HPSU Equity Fund provides larger equity investments than the standard HPSU program, targeting startups with breakthrough technology or highly disruptive business models. Investment amounts can be significantly higher, reflecting the greater capital needs of deep-tech and platform-based startups. The program also provides more intensive support including dedicated development advisors, access to international accelerators, and strategic partnership facilitation.

The fund targets Irish startups in deep technology areas including artificial intelligence, machine learning, advanced manufacturing, medtech, biotech, cybersecurity, and quantum computing. Companies should demonstrate significant intellectual property or proprietary technology that creates strong competitive barriers. The emphasis is on companies with the potential to become global leaders in their niche, requiring larger initial investment to develop their technology before market entry.

The Innovative HPSU Fund targets ventures with demonstrably novel technological propositions transcending incremental improvements. Applicants must evidence breakthrough potential validated through IP filings or prototype performance exceeding industry benchmarks. Investment amounts may exceed standard ceilings reflecting higher capital intensity in deep-tech commercialization. Companies in advanced materials and climate technology receive particular attention.

Enterprise Ireland establishes tailored milestone frameworks encompassing technical validation benchmarks, initial customer acquisition targets, and fundraising objectives within eighteen to twenty-four months. Recipients demonstrate progress toward international market penetration, often targeting the UK or North America. Board observer rights allow Enterprise Ireland to monitor execution without interfering operationally. Quarterly reporting covers cash runway, recruitment, and IP development.

Enterprise Ireland assesses dual regulatory pathway proposals examining medical device classification rationale, conformity assessment body selection justification, and clinical evidence generation strategy alignment with both European Medical Device Regulation and FDA premarket requirements. Technical file documentation demonstrating essential safety requirement compliance, biocompatibility testing according to ISO 10993 standards, and electrical safety verification per IEC 60601 standards substantiates regulatory preparedness. Quality management system implementation following ISO 13485 requirements satisfies both jurisdictional expectations simultaneously. Reimbursement pathway analysis identifying relevant diagnosis-related group codes, health technology assessment submission requirements, and payer engagement timelines strengthens commercial viability projections.

Enterprise Ireland maintains dedicated market advisors across twelve North American offices providing HPSU companies with customer introduction facilitation, distribution partner identification, and regulatory compliance navigation specific to Canadian provincial and US federal-state jurisdictional complexities. Trade mission participation enables curated meeting programmes with procurement decision-makers at target enterprise customers. Immigration attorney referral services assist founders obtaining E-2 investor visa or L-1 intracompany transfer authorization. Commercial lease negotiation guidance for establishing US subsidiary operational premises covers zoning compliance, build-out tenant improvement coordination, and commercial insurance procurement across unfamiliar liability exposure landscapes.